• 1
    Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Lewandowski B. SimpliRED D-dimer can reduce the diagnostic tests in suspected deep vein thrombosis. Lancet 1998; 351: 14056.
  • 2
    Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107: 12230.
  • 3
    Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, Iotti M, Tormene D, Simioni P, Pagnan A. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92: 199205.
  • 4
    Eichinger S, Kyrle PA. Duration of anticoagulation after initial idiopathic venous thrombosis – the swinging pendulum: risk assessment to predict recurrence. J Thromb Haemost 2009; 7(suppl. 1): 291295.
  • 5
    Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob G, Comerota AJ. Antithrombotic thereapy for venous thromboembolic disease. ACCP evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 454S545S.
  • 6
    Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 5236.
  • 7
    Schulman S, Rhedin A-S, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, Viering S, Nordlander S, Leijd B, Jönsson K-A, Hjorth M, Linder O, Boberg J, Duration of Anticoagulation Trl Sty Gp. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 16611665.
  • 8
    Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony P, Sanson C, Boissel JP. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103: 24532460.
  • 9
    Schulman S, Lindmarker P, Holmstrom M, Larfars G, Carlsson A, Nicol P, Svensson E, Ljungberg B, Viering S, Nordlander S, Leijd B, Jahed K, Hjorth M, Linder O, Beckman M. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4: 734742.
  • 10
    Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Lorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W. Three months versus one year of oral anticoagulant therapy for idiopathic deep vein thrombosis. N Eng JMed 2001; 345: 165169.
  • 11
    Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Imberti D, Poggio R, Ageno W, Pogliani E, Porro F, Zonzin P. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann. Intern. Med. 2003; 139: 1925.
  • 12
    Siragusa S, Malato A, Anastasio R, Cigna V, Milio G, Amato C, Bellisi M, Attanzio MT, Cormaci O, Pellegrino M, Dolce A, Casuccio A, Bajardi G, Mariani G. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood 2008; 112: 511515.
  • 13
    Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells PS, Julian JA, MacKinnon B, Weitz JI, Crowther M, Dolan S, Turpie AG, Geerts W, Solymoss S, Van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M, for the Extended Low-intensity Anticoagulation for Thrombo-Embolism investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recuttent venous thromboembolism. N Eng J Med 2003; 349: 631639.
  • 14
    Ridker PM, Goldhaber Z, Danielson SE, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ, for the PREVENT Investigators. Long-term, low-intensity warfarin therapy for prevention of recurrent venous thromboembolism. N Eng J Med 2003; 348: 14251434.
  • 15
    Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HG, Williamson IJ. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. Br Med J 2007; 334: 674.
  • 16
    Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AGG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian J, Johnston M, Douketis J, Roberts R, Van Nguyen P, Kassis J, Dolan S, Demers C, Desjardins L, Trowbridge A. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901907.
  • 17
    Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 17801789.
  • 18
    Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lărfars G, Leijd B, Linder O, Loogna E, Gustafsson C, Gröndahi A, Rhedin AS, Tŏrnebohm E, Lockner D, Johnsson H, Kobosko J, Malmros B, Arcini N, Saaw J, Stig R, Viering S. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393398.
  • 19
    Kearon C. Indefinite anticoagulation after a first episode of unprovoked venous thromboembolism: yes. J Thromb Haemost 2007; 5: 23305.
  • 20
    Levi M, Hovingh GK, Cannegieter SC, Vermeulen M, Buller HR, Rosendaal FR. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008; 111: 44716.
  • 21
    Locadia M, Bossuyt PM, Stalmeier PF, Sprangers MA, Van Dongen CJ, Middeldorp S, Bank I, Van Der MJ, Hamulyak K, Prins MH. Treatment of venous thromboembolism with vitamin K antagonists: patients’ health state valuations and treatment preferences. Thromb Haemost 2004; 92: 133613341.
  • 22
    Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 257S98S.
  • 23
    Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 7139.
  • 24
    McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006; 368: 3718.
  • 25
    Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T, Poli D, Lim W. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008; 149: 48190.
  • 26
    Rodger MA, Khan SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, Solymoss S, Crowther M, Perrier A, White R, Vickars L, Ramsay T, Betancourt MT, Kovacs MJ. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179: 417426.
  • 27
    Baglin T. What happens after venous thromboembolism. J Thromb Haemost 2009; 7(suppl. 1): 287290.